Currently, no standard of care exists for the treatment of relapsed or refractory acute myeloid leukemia (AML). We present our institutional

Abstract

Currently, no standard of care exists for the treatment of relapsed or refractory acute myeloid leukemia (AML). We present our institutional experience with using either CLAG-M or HAM-pegA, a novel regimen that includes pegaspargase. This is a retrospective comparison of 34 patients receiving CLAG-M and 10 receiving HAM-pegA as first salvage cytotoxic chemotherapy in the relapsed or refractory setting. Composite complete response rates were 47.1% for CLAG-M and 90% for HAM-pegA (p = 0.027). Event-free survival was significantly different in favor of HAM-pegA (p = 0.045), though overall survival was similar between groups. There were no significant differences in toxicities experienced by patients treated with the two regimens, including adverse events of special interest related to pegaspargase (venous thromboembolism, hemorrhage, hepatotoxicity, pancreatitis, and hypersensitivity reactions). HAM-pegA is a novel regimen for relapsed or refractory AML that resulted in improved response rates and similar toxicities compared to CLAG-M.

PMID: 32079074 [PubMed]

18:48

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

18:48

In reply to this message

pubmed: caandvteortroorpul

Management of Polycythemia Vera: A Survey of Canadian Physician Practice Patterns.

//www.ncbi.nlm.nih.gov/corehtml/query/egifs/https:--linkinghub.elsevier.com-ihub-images-PubMedLink.gif Related Articles

Management of Polycythemia Vera: A Survey of Canadian Physician Practice Patterns.

Clin Lymphoma Myeloma Leuk. 2019 01;19(1):e37-e42

Authors: Habib LA, Kuo KHM, Panzarella T, Gupta V, Trinkaus M